CoChat

Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities

Open access
Vaz, Miguel, Silva, Vítor, Monteiro, Cristina, Silvestre, Samuel · 2022 · Clinical Interventions in Aging

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Aducanumab is a monoclonal antibody selective for amyloid β (Aβ) aggregates. In June 2021, aducanumab became the first drug underlying the pathophysiology of Alzheimer's disease (AD) approved by the US Food and Drug Administration (FDA), under the accelerated approval pathway. The decision was based on the ability of aducanumab to remove Aβ plaques, without any evidence that the Aβ clearance is correlated with less cognitive or functional decline. This decision has generated a considerable debate in the scientific community, especially because the results from the two Phase 3 trials, EMERGE and ENGAGE, were divergent and, even after the post hoc analysis, the data were insufficient to prove aducanumab efficacy. Moreover, some researchers think that this approval will be an obstacle to the progress and also demonstrated concerns about aducanumab cost and its safety profile. The European Medicines Agency's rejection of aducanumab in December 2021 just brought more controversy over FDA's decision. Now, Biogen is designing the FDA's required confirmatory study, named ENVISION, which should be complete in 2026. Despite the controversy, the aducanumab showed to affect downstream tau pathology, which could open doors for a combination therapy approach for AD (anti-tau and anti-amyloid drug). This review summarizes the clinical development of aducanumab until regulatory agencies' decisions, the available trials data and the controversy over aducanumab approval for AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/cia.s325026

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Aducanumab timeline since futility analysis until regulatory agencies decisions.
Figure 1 Aducanumab timeline since futility analysis until regulatory agencies decisions.CC BY-NC · PubMed Central
Figure 2 Dose titration of aducanumab from 1 mg/kg to 10 mg/kg and magnetic resonance imaging monitoring.
Figure 2 Dose titration of aducanumab from 1 mg/kg to 10 mg/kg and magnetic resonance imaging monitoring.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 6

  1. World Health Organization. Global action plan on the public health response to dementia 2017–2025. Geneva:World Heal Organ; 2017: 27. Available from: http://www.who.int/mental_health/neurology/dementia/action_plan_2017_2025/en/. Accessed May 14, 2022.
  2. Eisai. Japan’s first committee on new drugs of the pharmaceutical affairs and food sanitation council seeks additional data; aducanumab remains under review. Eisai Global; 2021. Available from: https://www.eisai.com/news/2021/news2021101.html. Accessed April 9, 2022.
  3. Bussiere, 2013, Neurodegener Dis, 11, 2576
  4. Biogen. Update on regulatory review of aducanumab in the European Union. Biogen. Available from: https://investors.biogen.com/news-releases/news-release-details/update-regulatory-submission-aducanumab-european-union.; 2021. Accessed April 9, 2022.
  5. Institute for Clinical and Economic Review. ICER issues statement on the FDA’s approval of aducanumab for Alzheimer’s disease. ICER; 2021. Available from: https://icer.org/news-insights/press-releases/icer-issues-statement-on-The-fdas-approval-of-aducanumab-for-alzheimers-disease/. Accessed November 11, 2021.
  6. Association AF. Aduhelm lowers tau; registry to track real-world performance | ALZFORUM. Alzforum; 2021. Available from: https://www.alzforum.org/news/conference-coverage/aduhelm-lowers-tau-registry-track-real-world-performance. Accessed February 1, 2022.

Cited by

See all 183

Metadata

Authors
Vaz, M., Silva, V., Monteiro, C., & Silvestre, S.
Affiliations
University of Beira Interior (PT)
Corresponding author
Vaz, Miguel
Venue
Clinical Interventions in Aging
Published
2022-05
Volume
Volume 17
Pages
797-810
ISSN
  • 1176-9092 (ISSN-L)
  • 1178-1998
OpenAlex
W4280613528
Cited by
183
References
48
Citations by year
2026: 26 · 2025: 42 · 2024: 58 · 2023: 41 · 2022: 16
FWCI
5.40
Type
journal article
Language
en
Open access
Locations
  • Clinical Interventions in Aging (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
  • Programa Operacional Regional do Centro (CENTRO-01-0145-FEDER-000013)
  • Fundação para a Ciência e a Tecnologia (UID/Multi/00709, UID/Multi/00709/2019, 01-0145, COMPETE, POCI-01-0145, POCI-01-0145-FEDER-, COMPETE_2020, 00709/2019, POCI-01-, POCI-01-0145-FEDER- 007491, CENTRO-01-0145-FEDER-000013, 007491, 00709)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
aducanumab, Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, accelerated approval, tau pathology, combination therapy, drug safety, drug costs, regulatory decision-making
MeSH terms
Alzheimer Disease, Humans, United States, United States Food and Drug Administration, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities. https://app.cochat.ai/papers/10.2147/cia.s325026
The paper
Vaz, M., Silva, V., Monteiro, C., & Silvestre, S. (2022). Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities. Clinical Interventions in Aging. https://doi.org/10.2147/cia.s325026

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.